Wave Life Sciences Advances WVE-006 for AATD; Reports Q3 2026 Results
Wave Life Sciences reported Q3 2026 financials with $431.0M cash and $12M milestone due in 4Q 2026. The company is advancing clinical trials for RNA editing programs WVE-006, WVE-007, and WVE-008, while its proprietary technology yields new development candidates through partnerships including GSK.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed